Drug Search Results
More Filters [+]

ASP-6858

Alternative Names: asp-6858, asp6858, asp 6858
Latest Update: 2016-06-21
Latest Update Note: Clinical Trial Update

Product Description

for treating chronic kidney disease, with the hope of reducing the need for dialysis and to slow the progression of the disease.

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Astellas Pharma
Company Location: NEW YORK NY 10005
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ASP-6858

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

6858-CL-0001

P1

Completed

Healthy Volunteers

2016-01-01

Recent News Events

Date

Type

Title